Table 4.

Recommendations on the use of bempedoic acid in the Polish Guidelines

Recommendation	Class	Level
In patients with ASCVD who have not achieved the LDL-C target at their maximum tolerated dose of a statin and ezetimibe, combination therapy with bempedoic acid may be considered	IIb	B
In FH patients at very high risk not achieving the LDL-C target with the maximum tolerated dose of a statin and ezetimibe, combination with bempedoic acid may be considered	IIb	B
If a statin-based regimen is not tolerated at any dose (even after rechallenge), bempedoic acid or the combination of ezetimibe and bempedoic acid may be considered	IIb	B

Class IIb = definition: evidence/opinions do not sufficiently confirm the usefulness/efficacy of a specific treatment/procedure; suggestion of use: it may be considered. Level B = data obtained from a single randomised clinical trial or large non-randomized trials. (Reproduced with permission of Termedia [56••].)

ASCVD atherosclerotic cardiovascular disease, FH familial hypercholesterolemia, LDL-C low-density lipoprotein cholesterol